Emendo Biotherapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 100

Employees

  • Latest Deal Type
  • M&A

Emendo Biotherapeutics General Information

Description

Developer of gene editing tools designed to resolve bottlenecks in gene therapy. The company engages in using protein engineering to bring disruptive protein processes to resolve the bottleneck in gene therapy, enabling physicians to address disorders and diseases that are currently considered to be untreatable.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 111 Town Square Place
  • Suite 1507
  • Jersey City, NJ 07310
  • United States
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • 111 Town Square Place
  • Suite 1507
  • Jersey City, NJ 07310
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Emendo Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 15-Dec-2020 Completed Generating Revenue
2. Early Stage VC (Series B) 15-Jan-2020 Completed Generating Revenue
1. Early Stage VC (Series A) 05-Oct-2016 $12M $12M Completed Startup
To view Emendo Biotherapeutics’s complete valuation and funding history, request access »

Emendo Biotherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B3
Series B2
Series B1
Series A1 943,279 $0.000010 $0.27 $3.37 $3.37 1x $3.37 7.13%
Series A 3,564,000 $0.000010 $0.18 $2.25 $2.25 1x $2.25 26.95%
To view Emendo Biotherapeutics’s complete cap table history, request access »

Emendo Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of gene editing tools designed to resolve bottlenecks in gene therapy. The company engages in using protein en
Discovery Tools (Healthcare)
Jersey City, NJ
100 As of 2025

Cambridge, MA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Emendo Biotherapeutics Competitors (5)

One of Emendo Biotherapeutics’s 5 competitors is BlueRock Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BlueRock Therapeutics Formerly VC-backed Cambridge, MA
Editas Medicine Formerly VC-backed Cambridge, MA
Voyager Therapeutics Formerly VC-backed Lexington, MA
Spark Therapeutics Formerly VC-backed Philadelphia, PA
Beam Therapeutics Formerly VC-backed Cambridge, MA
You’re viewing 5 of 5 competitors. Get the full list »

Emendo Biotherapeutics Patents

Emendo Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026231945-A1 Biallelic knockout of bcl2l1 Pending 30-Apr-2025
WO-2026231941-A1 Biallelic knockout of parp1 Pending 30-Apr-2025
WO-2026136519-A1 Biallelic knockout of trbc 1/2 Pending 17-Dec-2024
EP-4766832-A1 Methods and compositions for modifying expression of a mutant transforming growth factor beta induced (tgfbi) allele Pending 23-Aug-2023
WO-2025043140-A1 Methods and compositions for modifying expression of a mutant transforming growth factor beta induced (tgfbi) allele Inactive 23-Aug-2023 A61P27/02
To view Emendo Biotherapeutics’s complete patent history, request access »

Emendo Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Emendo Biotherapeutics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
OrbiMed Growth/Expansion Minority
Takeda Ventures Corporate Venture Capital Minority
To view Emendo Biotherapeutics’s complete investors history, request access »

Emendo Biotherapeutics FAQs

  • When was Emendo Biotherapeutics founded?

    Emendo Biotherapeutics was founded in 2015.

  • Where is Emendo Biotherapeutics headquartered?

    Emendo Biotherapeutics is headquartered in Jersey City, NJ.

  • What is the size of Emendo Biotherapeutics?

    Emendo Biotherapeutics has 100 total employees.

  • What industry is Emendo Biotherapeutics in?

    Emendo Biotherapeutics’s primary industry is Discovery Tools (Healthcare).

  • Is Emendo Biotherapeutics a private or public company?

    Emendo Biotherapeutics is a Private company.

  • What is Emendo Biotherapeutics’s current revenue?

    The current revenue for Emendo Biotherapeutics is .

  • How much funding has Emendo Biotherapeutics raised over time?

    Emendo Biotherapeutics has raised $73M.

  • Who are Emendo Biotherapeutics’s investors?

    OrbiMed and Takeda Ventures have invested in Emendo Biotherapeutics.

  • Who are Emendo Biotherapeutics’s competitors?

    BlueRock Therapeutics, Editas Medicine, Voyager Therapeutics, Spark Therapeutics, and Beam Therapeutics are competitors of Emendo Biotherapeutics.

  • When was Emendo Biotherapeutics acquired?

    Emendo Biotherapeutics was acquired on 15-Dec-2020.

  • Who acquired Emendo Biotherapeutics?

    Emendo Biotherapeutics was acquired by AnGes.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process